← Back to Search

Exercise Training Program for Multiple Sclerosis (TEAAMS Trial)

N/A
Recruiting
Led By Robert W Motl, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up changes in walking scores from baseline, 4-months, and 8-months.

Summary

This trial will test if a remotely-delivered, racially-tailored exercise training program can improve walking dysfunction, symptoms, and health-related quality of life for African-Americans with MS who live in rural areas.

Who is the study for?
This trial is for African-American adults with Multiple Sclerosis living in rural areas, who are not very active physically, can use the internet and email, speak English, have been relapse-free for 30 days, and have mild to moderate walking difficulties. It's not for those at high risk of injury or death from intense exercise.
What is being tested?
The study tests a remote exercise program tailored for African-Americans with MS against a control group doing stretching exercises. The goal is to see if the program improves walking ability, symptoms, and quality of life immediately and over four months.
What are the potential side effects?
Since this trial involves an exercise program and stretching routines rather than medication or invasive procedures, side effects may include typical exercise-related issues such as muscle soreness or strain.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~changes in walking scores from baseline, 4-months, and 8-months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and changes in walking scores from baseline, 4-months, and 8-months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Walking Dysfunction
Secondary study objectives
Anxiety
Depressive Symptoms
Disability
+2 more
Other study objectives
Exercise Behavior

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Guidelines for Exercise in Multiple Sclerosis (GEMS)Experimental Treatment1 Intervention
Participants in this condition will receive a 4-month home-based, remotely supported aerobic and resistance exercise program based on the Guidelines for Exercise in Multiple Sclerosis (GEMS).
Group II: FLEX Stretching and Toning ProgramPlacebo Group1 Intervention
Participants in this condition will receive a 4-month home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamOTHER
1,647 Previous Clinical Trials
2,342,356 Total Patients Enrolled
38 Trials studying Multiple Sclerosis
45,263 Patients Enrolled for Multiple Sclerosis
Bristol-Myers SquibbIndustry Sponsor
2,688 Previous Clinical Trials
4,096,707 Total Patients Enrolled
14 Trials studying Multiple Sclerosis
21,414 Patients Enrolled for Multiple Sclerosis
University of Illinois at ChicagoLead Sponsor
639 Previous Clinical Trials
1,568,903 Total Patients Enrolled
15 Trials studying Multiple Sclerosis
1,719 Patients Enrolled for Multiple Sclerosis

Media Library

Guidelines for Exercise in Multiple Sclerosis (GEMS) Clinical Trial Eligibility Overview. Trial Name: NCT05516537 — N/A
Multiple Sclerosis Research Study Groups: Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
Multiple Sclerosis Clinical Trial 2023: Guidelines for Exercise in Multiple Sclerosis (GEMS) Highlights & Side Effects. Trial Name: NCT05516537 — N/A
Guidelines for Exercise in Multiple Sclerosis (GEMS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05516537 — N/A
Multiple Sclerosis Patient Testimony for trial: Trial Name: NCT05516537 — N/A
~24 spots leftby Aug 2025